APA (7th ed.) Citation

Karavayeva, T. A., Krupitsky, E. M., Barinov, A. N., Kolik, L. G., Ishchenko, K. A., & Khacheva, K. K. (2024). Efficacy and safety of Ranquilon® in the therapy of patients with anxiety associated with neurasthenia and adjustment disorder: Results of the double-blind, randomized, placebo-controlled, multicenter phase 3 clinical trial. Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation.

Chicago Style (17th ed.) Citation

Karavayeva, T. A., E. M. Krupitsky, A. N. Barinov, L. G. Kolik, K. A. Ishchenko, and K. K. Khacheva. Efficacy and Safety of Ranquilon® in the Therapy of Patients with Anxiety Associated with Neurasthenia and Adjustment Disorder: Results of the Double-blind, Randomized, Placebo-controlled, Multicenter Phase 3 Clinical Trial. Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation, 2024.

MLA (9th ed.) Citation

Karavayeva, T. A., et al. Efficacy and Safety of Ranquilon® in the Therapy of Patients with Anxiety Associated with Neurasthenia and Adjustment Disorder: Results of the Double-blind, Randomized, Placebo-controlled, Multicenter Phase 3 Clinical Trial. Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation, 2024.